Table 3.

Combinations of bortezomib with other chemotherapeutic agents as first line therapy

Study drugs		Reference	No of patients	Median assessable cycles	Major no of rate (CP+PR)	Response rates response	Follow up	Toxicities
Bortezomib +/− Dexamethasone	Phase II	Jagannath, Durie, et al 2005	40	Up to 6 cycles given	85%	28 patients had dex added and 64% showed improved response	12 patients underwent SCT	Neuropathy Fatigue Constipation Neutropenia
Bortezomib Dexamethasone	Phase II	Harousseau et al 2004	18	16 patients received 4 cycles	83%	CR 17% VGPR 11% PR 55%	Stem cells collected in all cases	Neuropathy
Bortezomib Doxorubicin Dexamethasone	Phase I/II	Oakervee et al 2005	21	19 patients received 4 cycles	95%	CR 24% n-CR 5% VGPR 33% PR 33%	18 patients underwent SCT with 44% CR and 95% ORR at 3 months	Neuropathy Postural hypotension Shingles Gastrointestinal
Bortezomib Melphalan Prednisolone	Phase I/II	Mateos et al 2005	53	3	84%	CR 28% n-CR 11% PR 45% MR 2%	90% alive at 7 months	Gastrointestinal Myelosuppression Infection Neuropathy
Bortezomib Thalidomide Dexamethasone	Phase I/II	Alexanian et al 2004	25	Up to 2 cycles given	84%	76% had >75% reduction in paraprotein +/− >l95% reduction in BJP	Median time to remission 0.6 months (compared with 1.1 months with Thal/Dex)12 patients underwent SCT	Infection Postural DVT Cytopenia
Bortezomib Thalidomide Dexamethasone	Phase I/II	Wang et al 2005	36	No more than 2 cycles needed for response	92%	CR 19% PR 73%	22 patients underwent SCT 89% in remission (31% CR) at 4 months	Neuropathy DVT Infections

Abbreviations: CR, complete response; DVT, deep vein thrombosis; MR, minor response; n-CR, near complete response; ORR, overall response rate (CR+PR+MR); PR, partial response; SCT, stem cell transplant; VGPR, very good partial remission.